Fact check
“The FDA is building on the guidance for industry entitled "Psychedelic Drugs: Considerations for Clinical Investigations".”
Reasoning
The claim states that the FDA is building on a specific guidance document titled "Psychedelic Drugs: Considerations for Clinical Investigations." Without any provided documents, statements, or references, there is no basis to verify whether such an action is occurring or has been announced.
On confidence: No supplied evidence was provided to confirm or refute the claim.
Important context
The claim pertains to FDA policy development regarding psychedelic drug research, which would typically be documented in FDA guidance releases or public statements.
Evidence
No retrievable evidence was found; the verdict rests on the reporting itself and is marked accordingly.
Limitations
The assessment is limited to the absence of supplied evidence; external sources were not consulted, and no inference can be made about the claim's truthfulness.
- Last verified:
- Oct 6, 2026, 4:16 AM CDT
- Pipeline:
- 2.1.0
- Claim type:
- Factual
Where this claim appeared
Design and Safety Considerations for Clinical Trials Involving Ibogaine Drug Products; Request for InformationFederal Register · Drug Administration, Human Services Department, Food, Health